UK- and EU- based applicants are invited to tender for the CRACK IT Challenges. The aim of the competition is to develop technologies with potential 3Rs benefits into new products and methodologies for the biosciences research community.
Funding of £1.2M is available through the CRACK IT Challenges competition to solve two Challenges identified jointly by the NC3Rs and Sponsors. This annual competition provides UK and EU-based academics and SMEs with the opportunity to apply to develop new 3Rs tools, technologies or approaches and engage with new partners.
The two 2022 Challenges were:
- Challenge 42 – T-ALERT: Animal-free tumourigenicity assessment of CAR-T and other genetically modified T cells
CAR-T (chimeric antigen receptor-T cell) therapies are emerging as effective therapeutic approaches in the treatment of some cancers. In vivo studies are used to assess the potential for tumourigenicity of these therapies and are invasive and often not predictive of clinical outcome.
This Two Phase Challenge aims to develop an in vitro assay that can reliably evaluate tumourigenicity of human-engineered T cell therapies with the potential to be applied to multiple immune cell types.
3Rs benefits: In vivo studies to assess tumourigenicity of modified T cells involve a minimum of 30 to 40 immunocompromised mice and can run for up to one year. Development of a predictive in vitro assay has the potential to replace the use of animals.
The Sponsors of this Challenge are Novartis, Takeda, AstraZeneca, Sonomabio, GentiBio.
- Challenge 43 – Thyroid Tox: Development of an in silico model to predict thyroid receptormediated human endocrine disruption
Endocrine disrupting chemicals are found in food, the environment and consumer products and can interact with endocrine related receptors including thyroid receptors. The full effect of these on human health and environmental species is not known.
This Single Phase Challenge aims to develop quantitative structure-activity relationship (QSAR) and molecular docking tools that reliably predict thyroid receptor-mediated human endocrine disruption.
3Rs benefits: The model developed through this Challenge aims to replace the animals used for thyroid receptor related endpoints in regulatory studies, delivering a reduction of 10-15% in the 2,500 animals used per chemical tested.
The Challenge is Sponsored by Shell and the NC3Rs will facilitate access to expert user input on the use of the EPA ToxCast database.
Further information about the CRACK IT Challenges competition process can be found on the CRACK IT Challenges-Website.
215 Euston Road, London, NW1 2BE
Tel: 020 7611 2233 | Fax: 020 7611 2260
Zurück zur Übersicht